153 related articles for article (PubMed ID: 29736936)
21. Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations.
Creary LE; Gangavarapu S; Caillier SJ; Cavalcante P; Frangiamore R; Lie BA; Bengtsson M; Harbo HF; Brauner S; Hollenbach JA; Oksenberg JR; Bernasconi P; Maniaol AH; Hammarström L; Mantegazza R; Fernández-Viña MA
Front Immunol; 2021; 12():667336. PubMed ID: 34163474
[TBL] [Abstract][Full Text] [Related]
22. Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in southern Iranian patients.
Yousefipour GA; Salami Z; Farjadian S
Iran J Immunol; 2009 Jun; 6(2):99-102. PubMed ID: 19561379
[TBL] [Abstract][Full Text] [Related]
23. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L
Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.
Niks EH; Kuks JB; Verschuuren JJ
J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):417-8. PubMed ID: 17056627
[TBL] [Abstract][Full Text] [Related]
25. HLA class I and class II polymorphisms in Saudi patients with myasthenia gravis.
Hajeer AH; Sawidan FA; Bohlega S; Saleh S; Sutton P; Shubaili A; Tahan AA; Al Jumah M
Int J Immunogenet; 2009 Jun; 36(3):169-72. PubMed ID: 19490212
[TBL] [Abstract][Full Text] [Related]
26. Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.
Verschuuren JJGM; Plomp JJ; Burden SJ; Zhang W; Fillié-Grijpma YE; Stienstra-van Es IE; Niks EH; Losen M; van der Maarel SM; Huijbers MG
Ann N Y Acad Sci; 2018 Feb; 1413(1):111-118. PubMed ID: 29356029
[TBL] [Abstract][Full Text] [Related]
27. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
28. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
29. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
Hurst RL; Gooch CL
Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
[TBL] [Abstract][Full Text] [Related]
30. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
[TBL] [Abstract][Full Text] [Related]
31. The association of human leukocyte antigen class II (HLA II) haplotypes with the risk of Latent autoimmune diabetes of adults (LADA): Evidence based on available data.
Chen W; Chen X; Zhang M; Huang Z
Gene; 2021 Jan; 767():145177. PubMed ID: 32998048
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
Sanadze AG; Sidnev DV; Karganov MIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
[TBL] [Abstract][Full Text] [Related]
33. [Seronegative myasthenia and myasthenia gravis with anti-MuSK antibody: a retrospective study of 20 cases].
Aubert S; Salort-Campana E; Franques J; Uzenot D; Pouget J
Rev Neurol (Paris); 2009 Nov; 165(11):901-10. PubMed ID: 19327804
[TBL] [Abstract][Full Text] [Related]
34. Rheumatoid arthritis in southern Spain: toward elucidation of a unifying role of the HLA class II region in disease predisposition.
Pascual M; Nieto A; López-Nevot MA; Ramal L; Matarán L; Caballero A; Alonso A; Martín J; Zanelli E
Arthritis Rheum; 2001 Feb; 44(2):307-14. PubMed ID: 11229460
[TBL] [Abstract][Full Text] [Related]
35. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
Yamada C; Teener JW; Davenport RD; Cooling L
J Clin Apher; 2015 Oct; 30(5):314-9. PubMed ID: 25557356
[TBL] [Abstract][Full Text] [Related]
36. Human Leucocyte Antigen B50 Is Associated with Conversion to Generalized Myasthenia Gravis in Patients with Pure Ocular Onset.
Tiftikcioglu BI; Uludag IF; Zorlu Y; Pirim İ; Sener U; Tokucoglu F; Korucuk M
Med Princ Pract; 2017; 26(1):71-77. PubMed ID: 27802446
[TBL] [Abstract][Full Text] [Related]
37. HLA and Singaporean Chinese myasthenia gravis.
Chan SH; Tan CB; Lin YN; Wee GB; Degli-Esposti MA; Dawkins RL
Int Arch Allergy Immunol; 1993; 101(2):119-25. PubMed ID: 8508049
[TBL] [Abstract][Full Text] [Related]
38. Myasthenia gravis patients with anti-MuSK antibodies.
Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
[TBL] [Abstract][Full Text] [Related]
39. Prepubertal anti-Musk positive myasthenia gravis with long remission.
Gungor-Tuncer O; Orhan EK; Yilmaz V; Parman Y; Oflazer P; Saruhan-Direskeneli G; Deymeer F
Neuromuscul Disord; 2014 Jan; 24(1):36-9. PubMed ID: 24074501
[TBL] [Abstract][Full Text] [Related]
40. [Effects of acetylcholinesterase inhibitors on patients with MuSK antibody positive myasthenia gravis].
Konishi T; Kousaka M; Yamakawa K; Matsui M; Ohta K
Rinsho Shinkeigaku; 2009 Oct; 49(10):660-3. PubMed ID: 19999149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
